IOBT

IO Biotech, Inc. [IOBT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IOBT Stock Summary

Top 10 Correlated ETFs

IOBT

Top 10 Correlated Stocks

IOBT

In the News

IOBT Financial details

Company Rating
-
Market Cap
102.12M
Income
-86.08M
Revenue
1.11M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
68
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.25
Forward P/E
-
PEG
0.94
P/S
-
P/B
0.63
P/C
-
P/FCF
-1.94
Quick Ratio
12.75
Current Ratio
12.96
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.15
EPS next Y
-
EPS next Q
-
EPS this Y
-20.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-6.98%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-46%
ROE
-61%
ROC
-0.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.816-2.64
52W High
-
52W Low
-
RSI
48
Rel Volume
7.32
Avg Volume
140.83K
Volume
1.03M
Perf Week
-16.31%
Perf Month
-47.31%
Perf Quarter
-14.64%
Perf Half Y
-10.16%
-
-
-
-
Beta
0.498
-
-
Volatility
0.1%, 0.41%
Prev Close
-5.26%
Price
0.8536
Change
-8.02%

Something similar

Top by Market Cap
BRH.DE
VOO
TSLA
LLY.SW
ABEA.DE
Top Correlated ETFs
PIFI
OPER
SMMU
META
FBL
Top Correlated Stocks
AUPH
TBLT
0EV1.L
RM
CCL
Similar Market Cap
0IP1.L
FDVA
ASAI.ST
PY
SUSD.L

Company Profile

Healthcare Biotechnology
  • Volume Average 140.83K
  • Market Capitalization 102.12M
  • Employee 68
  • CEO Dr. Mai-Britt Zocca Ph.D.
  • Headquarters Copenhagen,DK
  • IPO Date 2021-11-05
  • Website https://www.iobiotech.com

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.